Julie Yoo, general partner, Daisy Wolf, investment partner, and Will Shrank, venture partner, of a16z Bio + Health recently had a discussion with Chronis Manolis, SVP and Chief Pharmacy Officer of UPMC Health Plan about the approach payors and providers are taking towards anti-obesity medications. The conversation touched on topics such as pricing and prior authorization considerations in this context. This was the third episode in a series that focused on the science and supply of GLP-1s. In the previous episode, Brooke Boyarsky Pratt, founder and CEO of knownwell, shared insights about patient-centric medical homes. Before that, Carolyn Jasik, Chief Medical Officer at Omada Health provided a clinical perspective on GLP-1s. The experts’ insights shed light on the evolving landscape of anti-obesity medications and the factors that payors and providers are considering in their approach to these treatments. Stay tuned for more valuable discussions in this series on a16z Bio + Health.
